Cohance Lifesciences Ltd. News and Updates

Keep track of all breaking news on Cohance Lifesciences Ltd. from all sources in a single place.

Load latest

Cohance Lifesciences Ltd.

27 Jan 2025

1080.50

0.49%

Suven Pharma looks for 6x increase in revenue by FY35

Business Today

Looking to the future, Suven's Horizon 2 initiative which includes plans to incorporate capabilities in flow chemistry, messenger ribonucleic acid (mRNA), and peptides by fiscal year 2030 is expected to enhance the company's position in advanced drug modalities.

Number of FII/FPI investors increased from 201 to 218 in Mar 2025 qtr.

Cohance Lifesciences Ltd.

10 Dec 2024

1080.50

0.49%

How Will NJ Bio Acquisition Aid Suven Pharma?

NDTV Profit

We've seen an increase in enquiries on the back of China-free strategy, says Suven Pharma Executive Chairman Vivek Sharma. #suvenpharmanews #stockmarketnews

Cohance Lifesciences.. has an average target of 1402.50 from 2 brokers.

Cohance Lifesciences Ltd.

13 Nov 2024

1080.50

0.49%

Suven Pharma shares jump 6% after topline zooms 11% in Q2 earnings

Business Standard

Shares of Suven Pharmaceuticals surged up to 6.25 per cent at Rs 1,279 per share on the BSE in Wednesday's intraday deals

Number of FII/FPI investors increased from 201 to 218 in Mar 2025 qtr.

Suven Pharmaceuticals Q2 Results Live: Profit Rise by 3.33% YOY

livemint | 13 Nov 2024

Cohance Lifesciences Ltd.

12 Nov 2024

1080.50

0.49%

Suven Pharmaceuticals Results Earnings Call for Q2FY25

Conference Call with Suven Pharmaceuticals Management and Analysts on Q2FY25 Performance and Outlook. Listen to the full earnings transcript.

Cohance Lifesciences Ltd.

01 Nov 2024

1080.50

0.49%

Suven, Cohance aim to double combined biz revenue to Rs 6,000 cr by FY29

Business Standard

Merger-bound Suven Pharmaceuticals and Cohance Lifesciences aim to more than double their combined revenue to around Rs 6,000 crore by FY29 by undertaking both organic and inorganic growth routes, a top company official said. The entities reported a combined revenue of Rs 2,392 crore in FY24. The merged entity aims to put in place an aggressive plan to more than double revenue to Rs 6,000 crore by FY29 through both organic and inorganic growth routes, Suven Pharma Managing Director Prasada Raju said. The merger between Suven and Cohance has received approval from both NSE & BSE. As directed by National Company Law Tribunal (NCLT), the shareholders meeting of both Suven Pharmaceuticals and Cohance Lifesciences amalgamation will be held on November 28, 2024. Once finalised and approved, the combined entity will focus on three core growth drivers: pharma CDMO, specialty chemicals CDMO, and active pharmaceutical ingredients (APIs). "Together, we're building a powerhouse poised to...